Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Start with the lowest 0.25 mg dose and increase only every four weeks minimum
13 NONCLINICAL TOXICOLOGY NONCLINICAL TOXICOLOGY SECTION 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly
Safety considerations warrant discussion , particularly regarding gastrointestinal side effects that might affect medication adherence or nutritional status
Heart disease: You might need extra heart tests
These reheat well and pair with any protein and carbohydrate combination
